<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940912-2-00079</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=84 g=1 f=1 --> Schedule A  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Roche shall divest all of the assets and businesses of the Syva Business pursuant to the terms of this order. The associated assets identified in Paragraph I. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> I <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . (2) of this order shall include all assets, properties, business and goodwill, tangible and intangible, of the Syva Company in and relating to the development, manufacture, sale, distribution and marketing of drugs of abuse reagent products in the United States, including without limitation, the following:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Part 1  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. All rare reagent inventory (including antibody reagent pools, hapten conjugates, and detection labels), all inventory (finished and work in process), all sources of the antibodies (whether animals or cell lines), immunogens, commodities, cross-reactants, machinery, fixtures, equipment, vehicles, transportation facilities, furniture, tools, and other tangible personal property;  <!-- PJG 0012 frnewline --> 2. all customer lists, vendor lists, catalogs, sales promotion literature, advertising materials, technical information, management information systems, software, inventions, copyrights, trademarks, trade names, trade secrets, intellectual property, formulations, patents, technology know-how, specifications, designs, drawings, processes, quality assurance and control data, research materials, and information, relating to the manufacture and sale of the drugs of abuse reagent products, including without limitation information relating to FDA approvals and applications for FDA approvals, research and development data, data required under the Good Manufacturing Practices Guidelines, regulatory data packages, process validation, and documentation relating to Drug Enforcement Agency (``DEA'') approvals;  <!-- PJG 0012 frnewline --> 3. all rights, title and interest in and results of all research and development efforts of Syntex relating to improvements, developments, and variants of the Syva EMIT, EMIT II, and other drugs of abuse reagent product lines;  <!-- PJG 0012 frnewline --> 4. all rights, title and interest in and to the contracts entered into in the ordinary course of business with customers (together with associated bid and performance bonds), suppliers, sales representatives, distributors, agents, personal property lessors, personal property lessees, licensors, licensees, consignors, and consignees;  <!-- PJG 0012 frnewline --> 5. all rights under warranties and guarantees, express of implied;  <!-- PJG 0012 frnewline --> 6. all books, records and files; and  <!-- PJG 0012 frnewline --> 7. all items of prepaid expense.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Part 2  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. All assets, properties, business and goodwill, tangible and intangible, of the Syva Company in and relating primarily to the development, manufacture, sale, distribution and marketing of any in vitro diagnostic products other than drugs of abuse reagent products, including therapeutic drug monitoring reagent products, infectious disease reagent products, endocrine (thyroid) testing reagent products, and reagents used on the VISTA system (e.g., hormone, cancer, anemia, protein, and hepatitis/HIV testing);  <!-- PJG 0012 frnewline --> 2. inventory and storage capacity; and  <!-- PJG 0012 frnewline --> 3. all rigths, title and interest in and to owned or leased real property, together with appurtenances, licenses and permits.  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            